"All accepted abstracts will be published in the JGO"

Abstract submission:
Open on June 1, 2021 - August 15, 2021
Abstract acceptance notification by:
September 15, 2021

Early Registration
Open: June 21, 2021
Close: September 30, 2021

Contact us: asgo2021@gmail.com
Online Registration: www.asgo2021.org
Clinical Trial Protocol

Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study

Soo Jin Park,1 Ga Won Yim,2 Haerin Paik,1 Nara Lee,3 Seungmee Lee,4 Maria Lee,1 Hee Seung Kim1

1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
2Department of Obstetrics and Gynecology, Dongguk University Ilsan Hospital, Goyang, Korea
3Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea
4Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea

ABSTRACT

Background: The second-line chemotherapy using paclitaxel, carboplatin, and bevacizumab for treating platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer frequently cause chemotherapy-induced peripheral neuropathy (CIPN), which is significantly associated with deterioration of quality of life. Despite the potential of some agents to prevent and treat CIPN, and there is still a lack of evidence of the effect. Although selenium has been suggested as an antioxidant candidate to prevent CIPN, there are insufficient data regarding its effect due to its low dose by oral administration. Thus, we hypothesized intravenous administration of high-dose selenium (2,000 µg/day) at each cycle of the second-line chemotherapy would prevent and reduce CIPN in patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer.

Method: This trial is an investigator-initiated, phase III, double-blinded, randomized controlled trial to evaluate the efficacy and safety of intravenous administration of high-dose selenium (2,000 µg/day) for preventing CIPN in patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer who receive paclitaxel, carboplatin, and bevacizumab. A total of 68 patients will be randomly assigned to the experimental and control groups at a 1:1 ratio. As the primary endpoint, the incidence rate of CIPN three months after six cycles of chemotherapy will be compared between the two groups according to the combined criteria of neuropathy using the World Health Organization-CIPN criteria and Common Terminology Criteria for Adverse Events version 5.0. As secondary endpoints, we will compare adverse events, patient-reported quality of life, and requirement of concomitant drugs for reducing CIPN between the two groups.
Selenium for preventing peripheral neuropathy

Trial Registration: ClinicalTrials.gov Identifier: NCT04201561

Keywords: Selenium; Platinum-Sensitive; Recurrent; Ovarian Cancer; Chemotherapy; Neuropathy

INTRODUCTION

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common toxicities in taxane- and platinum-based chemotherapy for treating patients with ovarian, fallopian or primary peritoneal cancer [1-3], and up to 76% of the patients suffer from CIPN after the chemotherapy [4]. Moreover, the development of CIPN may lead to a dose reduction of chemotherapeutic agents by 17% [5], and may worsen the quality of life (QoL) of patients [6-11].

In particular, the clinical presentation of CIPN by paclitaxel or carboplatin is shown as symmetrical, glove-stocking distribution, and progressive pattern. Paclitaxel causes sensory and motor neuropathy, while carboplatin is mainly associated with sensory neuropathy [12]. Paclitaxel-induced neuropathy shows significant dose-limiting toxicity, whereas the reversibility of the neuropathy after cessation is not apparent [13,14]. On the other hand, carboplatin-induced neuropathy can develop during or several weeks after the administration and may cause more severe neurotoxicity when combined with other neurotoxic agents [12]. Moreover, bevacizumab used for treating recurrent ovarian, fallopian, or primary peritoneal cancer also causes CIPN [15]. Furthermore, the number of recurrences is associated with a more severe degree of CIPN, and the degree of CIPN remained stable six months after the last chemotherapy [2].

The assessment of CIPN includes clinician-based scales or patient-reported outcome measures because a single modality cannot reflect various aspects of CIPN such as pain, sensory and motor functions, and the degree of activities of daily living [16]. Furthermore, the incidence of CIPN varies widely with regards to the modalities of assessment [17]. Therefore, the evaluation of CIPN should be performed in diversified ways, and the evaluation should be done by combining both subjective and objective evaluation by physicians and patients.

Despite the frequent occurrence of CIPN and related deterioration of QoL in patients with ovarian, fallopian, or primary peritoneal cancer, the effective prevention and treatment strategy of CIPN is not well elucidated. For preventing CIPN, some agents such as magnesium, calcium, anticonvulsants, venlafaxine, vitamin E, and B6 have been evaluated, which still show a lack of evidence [18-22]. Although some drugs such as gabapentin, tricyclic antidepressants, anticonvulsants, non-steroidal anti-inflammatory drugs, and opioids are used to treat CIPN in the clinical setting [23], duloxetine, a serotonin-norepinephrine reuptake inhibitor, is known to be useful among them, however with limited relevant evidence in gynecologic cancer patients [24,25].

On the other hand, there are some shreds of evidence supporting selenium as a candidate for a neuroprotective agent for patients undergoing taxane- and platinum-based chemotherapy. Since CIPN can develop by oxidative stress and relevant mitochondrial dysfunction [26,27], selenium which acts as an antioxidant is expected to have the preventive potential to improve CIPN after taxane- and platinum-based chemotherapy because serum levels of selenium have been reported to decrease significantly in patients with gynecologic cancers [28,29].
previous study also supports this hypothesis because selenium supplementation increased the possibility of prevention or reduction of CIPN [18].

However, the effect of selenium for preventing CIPN might be reduced by oral administration of low-dose selenium. Previous studies failed to reveal the effect of selenium on the prevention of CIPN in cancer patients undergoing chemotherapy after oral administration of selenium of 100–800 µg/day [30-34]. In contrast, intravenous administration of high-dose selenium can enhance the effect of selenium with acceptable toxicity because previous studies where intravenous selenium was administered of up to 5,000 µg/day showed few adverse events [35-38]. Nonetheless, the most common grade 3 toxicity at 5,000 µg/day was restlessness and pain [38]. When considering these toxicity results it was decided to administer selenium at a lower dose than 5,000 µg/day since pain can affect the primary outcome of our study. Previously reported selenium-related toxic symptoms were garlic odor, brittle nail and hair, and gastrointestinal discomfort, and all of them were graded as mild according to the National Cancer Institute grading system [35]. Also, intravenous high-dose sodium selenite administration trials on severely ill patients have reported less than 2% of selenium-related toxicity events [39].

Therefore, we hypothesized that intravenous administration of high-dose selenium of 2,000 µg/day before chemotherapy using paclitaxel, carboplatin, and bevacizumab could prevent CIPN with acceptable adverse events for treating platinum-sensitive ovarian, fallopian or primary peritoneal cancer. The Institutional Review Board at Seoul National University Hospital approved this study in November 2019 (No. 1909-077-106), and this study was registered on Clinicaltrials.gov in December 2019 (No. NCT04201561).

**PROTOCOL**

1. **Objective**
   This phase III, double-blind, the randomized trial aims to evaluate the safety and efficacy of intravenous administration of high-dose selenium for preventing CIPN in patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer who receive paclitaxel, carboplatin and bevacizumab.

2. **Endpoints**
   The primary endpoint is to compare the incidence rate of CIPN at three months after six cycles of chemotherapy between the experimental (selenium) and control groups (placebo). The secondary endpoints are to compare adverse events, patient-reported QoL, and requirement of concomitant drugs for reducing CIPN between the two groups. CIPN will be assessed based on the combined criteria of the World Health Organization (WHO)-CIPN criteria and Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Table 1). According to this criterion, the incidence rate of CIPN at three months after six cycles of chemotherapy will be defined as the number of patients who will show grade 1 or higher neuropathy in terms of paresthesia, pain, or motor function divided by the total number of patients in each group [40,41]. Adverse events will be assessed at three weeks after each cycle of chemotherapy and three months after six cycles of chemotherapy according to the CTCAE version 5.0 [41]. Patient-reported QoL will be evaluated at baseline, at least three weeks after three and six cycles of chemotherapy, and at least three months after six cycles of chemotherapy by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
3. Study design

Investigator-initiated, phase III, single-center, double-blinded, randomized controlled trial.

## ELIGIBILITY CRITERIA

### 1. Inclusion criteria

1. Informed consent.
2. Age: 19–80 years old.
3. Epithelial ovarian cancer, fallopian cancer, or primary peritoneal cancer.
4. Complete or partial response after six to nine cycles of chemotherapy using paclitaxel and carboplatin as the first-line treatment according to Response Evaluation Criteria In Solid Tumors (RECIST) or Gynecologic Cancer Intergroup criteria (GCIG) after adjuvant chemotherapy for treating epithelial ovarian cancer [44,45].
5. Disease recurrence at least six months after the first-line chemotherapy.
6. No previous treatment with bevacizumab.
7. Plan of the second-line chemotherapy using paclitaxel, carboplatin, and bevacizumab.
8. Eastern Cooperative Oncology Group performance status 0 to 2.
9. No other concurrent disease affecting survival.
10. Normal hematologic, renal, and hepatic functions.

(EORTC QLQ-C30) [42] and the European Organization for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy-20 (EORTC CIPN-20) (Table 2) [43]. Moreover, the number, dose, and duration of gabapentin, duloxetine, and celecoxib used for treating CIPN as concomitant drugs will be compared between the two groups.

### 2. Schematic diagrams for the schedule

| Measurement                                      | Screening | 1st cycle | 2nd cycle | 3rd cycle | 4th cycle | 5th cycle | 6th cycle | Follow-up |
|--------------------------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Informed consent                                | 0         | 0         | 0         | 0         | 0         | 0         | 0         | 0         |
| Review of the inclusion and exclusion criteria  | 0         | 0         | 0         | 0         | 0         | 0         | 0         | 0         |
| WHO performance status                          | 0         | 0         | 0         | 0         | 0         | 0         | 0         | 0         |
| CIPN assessment                                  | 0         | 0         | 0         | 0         | 0         | 0         | 0         | 0         |
| Electrocardiogram                                | 0         | 0         | 0         | 0         | 0         | 0         | 0         | 0         |
| Laboratory test†                                 | 0         | 0         | 0         | 0         | 0         | 0         | 0         | 0         |
| Adverse events                                    | 0         | 0         | 0         | 0         | 0         | 0         | 0         | 0         |
| Quality of life‡                                  | 0         | 0         | 0         | 0         | 0         | 0         | 0         | 0         |

CIPN, chemotherapy-induced peripheral neuropathy; WHO, World Health Organization.
†Performed three weeks after each cycle of chemotherapy; †Complete blood count, including hematocrit, hemoglobin and platelet, and serum levels of aspartate aminotransferase, alanine aminotransferase, albumin, total bilirubin, and creatinine; §Performed within one week before each cycle of chemotherapy; ¶Quality of life is assessed by EORTC-QLQ-C30, EORTC-CIPN20 at least three weeks after three and six cycles of chemotherapy; □Quality of life is assessed by EORTC-QLQ-C30, EORTC-CIPN20 at least three months after six cycles of chemotherapy.

https://ejgo.org
2. Exclusion criteria
1) Pregnancy or breastfeeding.
2) Plan of secondary debulking surgery.
3) Previous treatment with bevacizumab.
4) No plan of the second-line chemotherapy using paclitaxel, carboplatin, and bevacizumab.
5) Other concurrent diseases affecting survival.
6) Underlying diseases such as diabetes, neuropathy, brain, or bone metastasis that can induce neuropathy.
7) Allergy to selenium.
8) Considered to be inappropriate to enroll in a clinical trial at the discretion of the investigator, participation would not be in the best interest of the subject, or that could prevent, limit or confound the assessments

SAMPLE SIZE JUSTIFICATION

In previous studies, the incidence rate of CIPN was 25% when combined with antioxidants [19], whereas it was at least 62.5% without antioxidants three months after chemotherapy using paclitaxel or cisplatin [20]. We expect that 25% of patients will develop CIPN when treated with selenium and chemotherapy, while 62.5% of patients in the control group will develop CIPN. Group sample sizes of 24 in each group are needed to achieve 80% power to detect a difference between the group proportions of −0.37, and the test statistic used is the two-sided Z-Test with unpooled variance, and the significance level of the test is 0.05. However, to evaluate the effect of selenium on the prevention of CIPN, the proportion of patients who can complete six cycles of chemotherapy using paclitaxel, carboplatin, and bevacizumab should be maintained above the lowest proportion. In the Gynecologic Oncology Group (GOG)-213 study, the percentage of patients who completed the planned 4–6 cycles was found to be 85.8% [15]. Therefore, a total of 68 cases, comprising 34 cases per group, is required to evaluate the efficacy of selenium administration, to assume 80% of completion rate for six cycles with consideration of the additional dropout rate of 10%.

RANDOMIZATION

After confirming the eligibility criteria, patients will be randomized into the experimental and control groups as a 1:1 ratio. Randomization table will be produced through a reproducible web-based program and managed by the third-party unblind staff who is an expert in gynecologic oncology (Fig. 1).

TREATMENT

1. Experimental group
Before administering the chemotherapeutic agents at each cycle, sodium selenite pentahydrate 2,000 µg/40 mL (Selentab®; Boryung Co., Ltd, Seoul, Korea) will be administered by intravenous infusion over two hours, similar to a previous study every three weeks for six cycles [46]. After that, paclitaxel (175 mg/m²), carboplatin (area under the curve 5), and bevacizumab (15 mg/kg) will be administered intravenously over 3, 1 and 1.5 hours respectively, for six cycles every three weeks according to GOG-231 protocol [15]. Since the
elimination half-life of selenium ranges from 17 to 29 hours [38], which is longer than that of paclitaxel (6 to 10 hours) or carboplatin (5 to 6 hours) [47], we decided that the intravenous administration of selenium two hours before chemotherapy might be enough to protect CIPN. After completion of six cycles of chemotherapy using paclitaxel, carboplatin, and bevacizumab, only bevacizumab will be administered as a maintenance therapy every three weeks until relapse, medical necessity or willingness of patients.

2. Control group
Before administering the chemotherapeutic agents at each cycle, normal saline of 40 ml will be administered by intravenous infusion over two hours as a placebo every three weeks for six cycles. After that, paclitaxel (175 mg/m²), carboplatin (area under the curve 5), and bevacizumab (15 mg/kg) will be administered intravenously over 3, 1 and 1.5 hours respectively for six cycles every three weeks based on GOG-213 protocol [15]. After completion of six cycles of the combination of chemotherapy, only bevacizumab will be administered as a maintenance therapy every three weeks until relapse, medical necessity, or willingness of patients.

MONITORING
Adverse events will be evaluated periodically on the Data Safety and Monitoring Board composed of independent experts without conflict of interest in this study.

STATISTICAL ANALYSIS
Both Intention-To-Treat (ITT) and Per-Protocol (PP) populations will be analyzed. The incidence rate of CIPN three months after six cycles of chemotherapy will be evaluated by

Platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer

Randomization

Experimental group
Six cycles of
Sodium selenite pentahydrate (2,000 µg/40 mL)
Paclitaxel (175 mg/m²)
Carboplatin (AUC 5)
Bevacizumab (15 mg/kg)
every 3 weeks

+ Maintenance of
Bevacizumab (15 mg/kg)
every 3 weeks

Control group
Six cycles of
Normal saline (40 mL)
Paclitaxel (175 mg/m²)
Carboplatin (AUC 5)
Bevacizumab (15 mg/kg)
every 3 weeks

+ Maintenance of
Bevacizumab (15 mg/kg)
every 3 weeks

Fig. 1. Schema of this study.
AUC, area under the curve.
using the Logistic Regression analysis to analyze the odds ratio. Adverse events and patient-reported QoL will be compared between the two groups by using ordinal logistic regression and generalized estimating equations to see if there are differences between the two groups. The number, dose, and duration of the combined medication will be compared and evaluated using the χ² or Fisher’s exact test, and the Student-T or Mann-Whitney U test.

DISCUSSION

This is the first study to evaluate the effect of intravenous high-dose selenium administration for the prevention of CIPN. However, few data have shown the effect of selenium on the prevention of CIPN in terms of a well-designed clinical trial. We designed this phase III trial to show the impact of selenium compared to placebo and evaluating CIPN in several aspects. The result of this study will further contribute to conducting a well-designed large-scale trial to evaluate the efficacy of selenium for CIPN prevention.

In addition, previous trials on the prevention of CIPN are known to have shown little positive results. This is because the main outcome of these trials was the various symptoms of neuropathy, subjective evaluation by the clinicians, and subjective evaluation by the patient [48]. Since these limitations also hinder to design a relevant phase II trial, we designed this phase III randomized controlled trial to practically evaluate the preventive effect of selenium on CIPN by hypothesizing the selenium dose and schedule, expected to show little toxicity and maximal effect with the uniform assessment modality for evaluating CIPN. In the future, the results from this study will act as a reference for designing large-scale relevant phase III trials. In addition, the limitation of this clinical trial is that long-term follow-up of CIPN does not occur beyond 3 months after the last chemotherapy. Therefore the long-term effect of selenium should be evaluated in further study.

Furthermore, the cumulative toxicity might increase the incidence of CIPN at the time of enrollment because some degree of patients is known to have persistent neuropathic symptom six months after last chemotherapy. However, chemo-naïve patients might complain neuropathic symptoms, which is not associated with chemotherapy [2], and patients who have undergone chemotherapy will be able to recognize and tell whether the symptoms are neuropathy associated with chemotherapy. In addition, since patients who have previously experienced neuropathy caused by anticancer drugs want to avoid these side effects again, it is considered that the prevention of CIPN for patients receiving second-line treatment would be more meaningful than the first-line treatment.

ACKNOWLEDGEMENTS

Boryung Co., Ltd supported this work by offering the investigational products. The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

The Medical Research Collaborating Center (MRCC) from Seoul National University Hospital advised sample size calculation for this trial.
REFERENCES

1. Bonhof CS, Mols F, Vos MC, Pijnenborg JM, Boll D, Vreugdenhil G, et al. Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: a longitudinal study. Gynecol Oncol 2018;149:455-63.

2. Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol 2014;135:510-7.

3. Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 2015;54:2461-70.

4. Seretny M, Currie GL, Sena ES, Rammarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155:2461-70.

5. Bhattachar A, Gilmore S, Goloubova O, Pelser C, Medeiros M, Chumsri S, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus 2014;3:366.

6. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 2003;98:822-31.

7. Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients. Support Care Cancer 2012;20:877-81.

8. Griffith KA, Couture DJ, Zhu S, Pandya N, Johantgen ME, Cavaletti G, et al. Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer 2014;22:1161-9.

9. Kim BJ, Park HR, Roh HJ, Jeong DS, Kim BS, Park KW, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 2010;19:1097-103.

10. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013;31:2699-707.

11. Richter R, Oskay-Oezcelik G, Chekerov R, Pilger A, Hindenburg HJ, Sommer H, et al. Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology. Anticancer Res 2012;32:969-76.

12. Haushfe RH, Schlisky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33:15-49.

13. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20 Suppl 3:1-15.

14. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of taxol. J Natl Cancer Inst Monogr 1993;15:10-15.

15. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:779-91.
16. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000;11:509-13.

17. Molassiotis A, Cheng HL, Lopez V, Au JS, Chan A, Bandla A, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019;19:132.

18. Erken HA, Koç ER, Yazıcı H, Yay A, Önder GÖ, Sarıcı SF. Selenium partially prevents cisplatin-induced neurotoxicity: a preliminary study. Neurotoxicology 2014;42:71-5.

19. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005;64:26-31.

20. Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage 2006;32:237-44.

21. Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 2012;12:355.

22. Schloss JM, Colosimo M, Vitetta L. Chemotherapy-induced peripheral neuropathy management. Alexandria, VA: American Society of Clinical Oncology; 2016.

23. Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009;145:3-14.

24. Suzuki H, Shinohara A, Ohno I, Mitsunaga S, Takeno MK, Funazaki H, et al. The effect of duloxetine on chemotherapy-induced peripheral neuropathy in advanced pancreatic cancer patients receiving gemcitabine plus nab-paclitaxel treatment. Alexandria, VA: American Society of Clinical Oncology; 2017.

25. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309:1359-67.

26. Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 2015;596:90-107.

27. Duggett NA, Griffiths LA, McKenna OE, de Santis V, Yongsanguanchai N, Mokori EB, et al. Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy. Neuroscience 2016;333:13-26.

28. Shenkin A. Selenium in intravenous nutrition. Gastroenterology 2009;137 Suppl:S61-9.

29. Sundström H, Korpela H, Viinikka L, Kauppila A. Serum selenium and glutathione peroxidase, and plasma lipid peroxides in uterine, ovarian or vulvar cancer, and their responses to antioxidants in patients with ovarian cancer. Cancer Lett 1984;24:1-10.

30. Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggiernaith W, et al. Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck. World J Clin Oncol 2015;6:166-73.

31. Muecke R, Schomburg L, Glatzel M, Berndt-Skorka R, Baaske D, Reichl B, et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 2010;78:828-35.

32. Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 2004;40:1713-23.
33. Büntzel J, Riesenbeck D, Glätzel M, Berndt-Skorka R, Riedel T, Mücke R, et al. Limited effects of selenium substitution in the prevention of radiation-associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Res 2010;30:1829-32.

PUBMED

34. Mücke R, Micke O, Schomburg L, Glätzel M, Reichl B, Kisters K, et al. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. Integr Cancer Ther 2014;13:463-7.

PUBMED | CROSSREF

35. Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC, et al. A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 2004;18:69-74.

PUBMED | CROSSREF

36. Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, Creaven PJ, et al. A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemother Pharmacol 2008;62:499-508.

PUBMED | CROSSREF

37. Asfour IA, Fayek M, Raouf S, Soliman M, Hegab HM, El-Desoky H, et al. The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival. Biol Trace Elem Res 2007;120:1-10.

PUBMED | CROSSREF

38. Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.

PUBMED | CROSSREF

41. U.S. Department of Health and Human Services. CTCAE v5.0, common terminology criteria for adverse events [Internet]. Washington, D.C.: U.S. Department of Health and Human Services; 2017 [cited 2020 Oct 15]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.

42. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004;13:863-8.

PUBMED | CROSSREF

43. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.

PUBMED | CROSSREF

44. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011;21:419-23.